Wayrilz

Wayrilz is an oral reversible BTK inhibitor indicated for adults with chronic immune thrombocytopenia (ITP). It works by modulating immune pathways to increase platelet counts and reduce the risk of bleeding, offering a convenient twice-daily oral treatment option.

Molecule Details :

  • Molecule Name :

    Rilzabrutinib
  • Innovator :

    GENZYME CORP
  • Approval Date :

    29-Aug-25
  • NCE-1 Date :

    29-Aug-29
  • NCE Date :

    29-Aug-30
  • Dosage Form :

    Oral Tablet
  • Strength :

    400MG
  • Therapeutic Category :

    Immunomodulators
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    23
  • 2026 :

    133
  • 2027 :

    223
  • 2028 :

    345
  • 2029 :

    445
  • 2030 :

    562
  • 2031 :

    677
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?